Diacylglycerol (DAG) (DAG)

Diacylglycerol (DAG) is a vital lipid second messenger that plays a central role in eukaryotic signal transduction (StatPearls, 2023). It is primarily generated in the plasma membrane through the hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP2) by the enzyme phospholipase C (PLC) following the activation of G protein-coupled receptors or receptor tyrosine kinases (PubChem, 2024). Once produced, DAG remains membrane-bound and recruits various effector proteins containing C1 domains, most notably members of the Protein Kinase C (PKC) family (UniProt, 2024). These effectors then phosphorylate downstream targets to regulate cell growth, differentiation, and metabolism. Beyond PKC, DAG also modulates the activity of other signaling proteins like RasGRP and Munc13, influencing Ras signaling and neurotransmitter release (Wikipedia, 2024). Pathologically, chronically elevated DAG levels are strongly linked to insulin resistance in obesity and type 2 diabetes, as well as to the promotion of tumorigenesis through sustained PKC activation (Nature Reviews Endocrinology, 2021). Pharmacologically, DAG signaling is manipulated using mimetics like bryostatins or by targeting the enzymes responsible for its metabolism, such as diacylglycerol kinases (DGKs) (PubMed, 2022).

Other names

Diglyceride1,2-Diacylglycerolsn-1,2-DiacylglycerolGlyceride diester

Drugs targeting the diacylglycerol pathway typically act as mimetics that bind to the C1 domains of effector proteins, such as Protein Kinase C (PKC), to induce their translocation to the membrane and subsequent activation, or they modulate endogenous DAG levels by inhibiting enzymes like diacylglycerol lipase or diacylglycerol kinase (StatPearls, 2023; PubMed, 2022).